Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ATA-3219 by Atara Biotherapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
ATA-3219 is under clinical development by Atara Biotherapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
ATA-3219 by Atara Biotherapeutics for Follicular Lymphoma: Likelihood of Approval
ATA-3219 is under clinical development by Atara Biotherapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
ATA-3219 by Atara Biotherapeutics for Mantle Cell Lymphoma: Likelihood of Approval
ATA-3219 is under clinical development by Atara Biotherapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
ATA-3219 by Atara Biotherapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ATA-3219 is under clinical development by Atara Biotherapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
Risk adjusted net present value: What is the current valuation of Atara Biotherapeutics's ATA-3219?
ATA-3219 is a gene-modified cell therapy commercialized by Atara Biotherapeutics, with a leading Phase I program in Diffuse Large B-Cell...